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ABSTRACT  
Doxorubicin (DOX) is an excellent antineoplastic agent used for the treatment of hematologi-
cal and solid malignancies. The aqueous extract of Bombyx mori (BMAE) contains amino ac-
ids and some flavonoids with obvious cardioprotective effect. The aim of this study was to 
investigate the possible protective effect of BMAE against DOX-induced cardiotoxicity and 
its underlying mechanisms on murine model. The metabolic profiling of BMAE was carried 
out by Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) and the 
amino acid profiling by HPLC method using fluorescence detector (HPLC-FLD). The bio-
chemical parameter like caspase-3, tumor necrosis factor–alpha (TNF—α), interleukin -6 (IL-
6), creatine kinase-MB (CK-MB), lactate dehydrogenase (LDH) and malondialdehyde 
(MDA) were studied. Tissue damage was further evaluated by histopathological studies. The 
metabolic profiling of BMAE exhibited presence of quercetin 7-O-β-D-glucoside, kaempferol 
7-O-β-D-glucopyranoside, coumaric acid glucoside, 2-hydroxy-nonadecanoic acid and 9,12-
dihydroxy stearic acid as important constituents. The amino acid profile by HPLC-FLD 
showed presence of 17 amino acids. The BMAE showed prominent free radical scavenging 
activity when assessed by the H2O2 and super-oxide method. The results of present investiga-
tion showed protection against DOX-induced oxidative stress (lipid peroxidation), by revert-
ing activities of apoptotic markers (caspase-3 and TNF-α), cardiac markers (CK-MB and 
LDH activities) as well as pro-inflammatory marker IL-6 followed by oral administration of 
BMAE. In addition, results of histopathology also supported well the above results. It was ob-
served that BMAE protects DOX-induced cardiotoxicity by virtue of its antioxidants possibly 
by flavonoids and amino acids. 
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INTRODUCTION 
Doxorubicin (DOX), is a naturally occur-
ring anthracycline and widely used for the 
treatment of a range of human malignancies 
including hematomas and solid tumors (El-
baky et al., 2010). The use of doxorubicin 
has been associated with severe toxic effects 
and most dangerous one is the dose-depend-
ent cardiotoxicity, leading to cardiomyopa-
thy and eventually congestive heart failure. 
Cardiotoxicity includes a wide range of car-
diac effects from small changes in blood 
pressure and arrhythmias to cardiomyopathy 
(Schimmel et al., 2004).  
Acute DOX cardiotoxicity occurs within 
2-3 days of its administration. Studies have 
shown that DOX causes cardiotoxicity 
through mechanisms other than those medi-
ating its antitumor effect (Khan et al., 2014). 
However, it appears that the induction of an 
oxidative stress within myocardial tissue 
constitutes a common denominator (Vergely 
et al., 2007). It is usually arbitrated through 
lipid peroxidation and inhibition of long fatty 
acid oxidation in cardiac tissues. The oxida-
tive stress, lipid peroxidation and mitochon-
drial dysfunction have been associated with 
DOX-induced cardiomyopathy (Nohl et al., 
1998). 
DOX generates reactive oxygen species 
(ROS) via several mechanisms (Malisza and 
Hasinoff, 1995) and can directly form com-
plexes with ferrous ion within the cell. These 
complexes are pertinent to generate ROS in 
the presence or the absence of reducing 
components (Vergely et al., 2007). The in-
vestigations showed that animals treated 
with compounds of antioxidant potential pro-
tects heart against DOX induced toxicity 
(Nazeyrollas et al., 1999; Liu et al., 2002). 
Unani System of Medicine offers a number 
of cardioprotective and cardiotonic single 
and compound drugs which have been men-
tioned by ancient renowned Unani physi-
cians in classical literatures including 
Khameera Abresham Sada, Khameera 
Gaozabansada, Khameera Abresham Uood 
Mastagi Wala etc (Ahmad et al., 2010). Sci-
entific studies have proven the cardioprotec-
tive effect of some Unani compound formu-
lations such as Khameera Abresham Hakeem 
Arshad Wala (KAHAW) (Goyal et al., 
2010), Khamira Abresham Uood Mastigi 
Wala (KAUM), Khamira Abresham Sada 
(KAS) etc (Kabeer, 1951). which are used by 
Unani Physicians since ancient times.  
Abresham, a cocoon of Bombyx mori 
(silkworm) is the main ingredient of KA-
HAW, KAUM and KAS. Therefore, it was 
thought worthwhile to carry out scientific 
validation of cardioprotective potential of 
Abresham. The two main constituents of 
abresham are fibroin (70 %) and sericin 
(25 %). The non sericin components consist 
mainly of carbohydrates, salt, waxes (Mon-
dal et al., 2007), and some flavonoids deriva-
tives. The main flavonoids are quercetin gly-
cosides (quercetin 5-O-beta-D-glucoside, 
quercetin 7-O-beta-D-glucoside, and querce-
tin 4-O-beta-D-glucoside) with two 
kaempferol glycosides (kaempferol 5-O-
beta-D-glucoside and kaempferol 7-O-beta-
D-glucoside) (Kurioka and Yamazaki, 2002). 
Sericin and fibroin are rich sources of amino 
acids (Schroeder et al., 1955), which can 
play an important role in myocardial protec-
tion (Julia et al., 1990), since shielding effect 
of amino acids has already been reported to 
significantly improve the recovery of cardiac 
function (Shug et al., 1994). However, fla-
vonoids act as scavengers of reactive oxygen 
species (Haenen et al., 1993). Mahmood and 
colleagues (2013) have suggested the potent 
antioxidative activity of B. mori cocoon is 
mainly due to rich source of free amino acids 
and flavonoid compounds present in them 
(Kurioka and Yamazaki, 2002). 
Most of the previous studies are either on 
alcoholic extract or on crude B. mori, where-
as, according to official Unani Pharmacopoe-
ia and other literature of traditional system of 
medicine aqueous decoction is used in most 
of the Unani formulations. Therefore, the 
purpose of the present study was to elucidate 
the potential of standardized B. mori aqueous 
extract (BMAE) against DOX induced car-
diomyopathy in rats. 
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MATERIALS AND METHODS 
Experimental animals 
Adult male wistar albino rats (10- 
12 week old), having body weight of 150-
200 g, were used. Animals were acclimatized 
and housed under controlled conditions of 
illumination (12 h light/dark cycles) with 
temperature of 20-25 °C and relative humidi-
ty of 30 + 5 %. Standard pellet diet 
(Ashirwad Rat Feed, Chandigarh, India) and 
water ad libitum were provided to the ani-
mals throughout the study period. The study 
was approved by the Institutional Animal 
Ethics Committee (CPCSEA registration no 
173/CPCSEA) of Jamia Hamdard, New Del-
hi. 
 
Drugs and chemicals 
B. mori was procured from the local drug 
market and identified by Dr. A. Ahmad, De-
partment of Ilmul Advia, Faculty of Medi-
cine, Hamdard University, New Delhi. A 
voucher specimen was deposited in the her-
barium of the Bioactive Natural Product La-
boratory (Specimen no-54/BM/BNPL/ 
2012). DOX was obtained as Adrim injec-
tion (Dabur Pharmaceuticals, India) whereas 
desferrioxamine as Desferal injection (No-
vartis Pharmaceuticals, Switzerland). All the 
other chemicals used were of analytical 
grade. 
 
Preparation of extract 
The aqueous extract of Bombyx mori 
(BMAE) was prepared similar to the method 
used for development of traditional formula-
tions. In brief, the cocoons were sliced into 
small pieces and 200 g of it was placed in 
round bottom flask of 5 L capacity. The ex-
traction was carried out using reflux conden-
ser and double distilled water (DDW) (3 L) 
as solvent for two hours on water bath. It 
was kept aside overnight with occasional 
shaking and press filtered using muslin cloth. 
The residue left was washed with fresh sol-
vent (DDW). The extract and washings were 
pooled and concentrated in rota-vapour, fol-
lowed by drying in lyophilizer (extractive 
value 5.66 % w/w) to get free flowing pow-
der. It was stored in cool place (4 °C) till 
analysis and bioactivity. 
 
Metabolic profiling of extract by using 
UPLC-MS 
The freeze dried powdered of BMAE 
was dissolved in LCMS grade acetonitrile 
and water (100 µg mL-1) and filtered. The 
constituents were analyzed on a Water’s 
ACQUITY UPLCTM system (Serial No# F09 
UPB 920M; Model Code# UPB; Waters 
Corp., MA, USA) equipped with a binary 
solvent delivery system, an auto-sampler, 
column manager and a tunable MS detector 
(Serial No# JAA 272; SYNAPT; WATERS, 
Manchester, UK). Chromatographic separa-
tion was performed on a Water’s ACQUITY 
UPLCTM BEH C18 (100.0 mm х 2.1 mm; 
1.7 μm) column at 40 ± 5 °C. The UPLC 
analysis was done using water: acetonitrile 
(90:10; v/v), as solvent system in gradient 
elution. The flow rate of the mobile phase 
was kept at 0.35 mL min-1 and 10 μL of 
sample solution was injected in each run. 
The total chromatographic run time was 
30 min. The column and auto-sampler were 
maintained at 40 ± 5 and 25 ± 5 °C, respec-
tively whereas the pressure of the system 
was set to 15000 psi. 
 
Determination of free amino acids by using 
HPLC-FLD 
Determination of amino acids as their re-
spective 6-aminoquinolyl-N-hydroxysuccini-
midyl carbamate (AQC) derivatives were 
successfully applied for assessing free amino 
acid levels in BMAE based on the Waters 
AccQ.Tag™ method for high performance 
liquid chromatography (HPLC) (Kabelová et 
al., 2009). 
 
Determination of in vitro anti-oxidant po-
tential 
Superoxide radical scavenging and hy-
drogen peroxide scavenging potentials of 
BMAE were determined as per the methods 
reported by Amir and colleagues (2011) in 
the concentration range of 5.0-35 μg mL-1 
using ascorbic acid as standard. 
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In vivo cardioprotective activity 
Animals and dosing schedule  
The animals were housed in polypropyl-
ene cages (size 40 x 25 x 16 cm) in groups of 
six rats per cage. These were allowed to ac-
climatize for one week before the experi-
ments and were given free access to standard 
laboratory animal diet and water ad libitum. 
After acclimatization rats were randomly as-
signed into five groups of six animals each. 
Group 1 (vehicle control), rats were treated 
with 0.5 % carboxy methyl cellulose (CMC) 
in normal saline (2 mL/Kg/p.o./day) for 30 
days. Group 2 (pathogenic control; DOX), 
received 0.5 % CMC in normal saline 
(2 mL/Kg/p.o./day) for 30 days along with 
doxorubicin (20 mg/Kg, single i.p. injection) 
on 31st day. Group 3 (BMAE 30) animals 
were administered with BMAE (30 mg/Kg/ 
p.o./day) for 30 days and DOX (20 mg/Kg, 
single i.p. injection) on 31st day. Similarly, 
group 4 (BMAE 60) animals were adminis-
tered with BMAE (60 mg/Kg/p.o./day) for 
30 days and DOX (20 mg/Kg, single i.p. in-
jection) on 31st day. Group 5 (DFX) was 
given desferrioxamine (50 mg/Kg/i.v. injec-
tion /day) for 30 days with DOX (20 mg/Kg, 
single i.p. injection) on 31st day (Ayla et al., 
2011; Sharma et al., 2011). At the end of 
treatment (i.e. 31st day), animals were fasted 
overnight (12 h) and blood samples were 
collected from retro-orbital plexus under 
mild ether anesthesia for separation of se-
rum. Further, animals were sacrificed by 
cervical dislocation and heart was excised, 
which was stored at -80 °C for histopatholo-
gy and biochemical estimation. 
 
Biochemical estimation 
CK-MB and LDH activity (Reckon Dia-
gnostics Pvt. Ltd, India) (Lum and Gambino, 
1974), IL-6 (Ray Biotech) (Helle et al., 
1991), TNF-α (e-Bioscience, Inc., USA) 
(Lehmann et al., 2008) and protein (Lowry et 
al., 1951) were measured in serum as per 
standard methods. Similarly, caspase-3 was 
measured (Bio Vision, Inc., USA) (Jaeschke 
et al., 1998). Lipid peroxidation (Iqbal et al., 
2008) and protein (Lowry et al., 1951) were 
estimated in heart tissue homogenate as per 
the standard protocol.  
 
Histopathological examination 
The heart tissues were fixed in 10 % 
formalin and sections were prepared with 
thickness up to 5.0 µm. These were stained 
with hematoxylin and eosin for histopatho-
logical evaluation of heart sections and were 
carried out by a pathologist unaware of 
groups (Belur et al., 1990). 
 
Statistical analysis 
The data is expressed as mean ± SD. Sta-
tistical differences between means were de-
termined by one-way analysis of variance 
(ANOVA), followed by Dunnett’s t test. The 
values of P<0.05 were considered as signifi-
cant. 
 
RESULTS 
Quality control of BMAE 
The extraction of B. mori as per the tradi-
tional method resulted in 5.66 % w/w of 
BMAE, which was further subjected to the 
quality control analysis. The metabolic pro-
filing of BMAE by UPLC-qTOF-MS fol-
lowed by tentative structure assignment us-
ing m/z and literature showed identification 
and separation of twenty eight constituents 
out of which quercetin 7-O-β-D-glucoside, 
kaempferol 7-O-β-D-glucopyranoside, cou-
maric acid glucoside, 2-hydroxy-nonadeca-
noic acid, 9,12-dihydroxy stearic acid were 
present in highest amount as compared to 
other constituents (Table 1). The amino acid 
profiling by HPLC-FLD revealed presence 
of 17 amino acids v.i.z. proline, cysteine, 
methionine, aspartic acid, serine, alanine, 
lysine, leucine, histidine, threonine, glycine, 
arginine, tyrosine, valine, isoleucine and 
phenylalanine (Figure 1). The content of cys-
teine, methionine and proline were found 
highest, whereas isoleucine and tyrosine 
were found lowest (Table 2). 
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Table 1: Metabolites tentatively identified with their m/z ratio and literature in the Bombyx mori 
[UPLC/qTOF/MS study] 
Bombyx mori m/z Chemical formula Molecular weight Chemical name  
S. No Rt 
1 3.77 281.14 C15H22O5 282.14 Oxyhumulinic acid 
2 4.44 537.31 C30H42N4O5 538.31 PheLeuPhe Ile 
3 4.96 497.44 C34H58O2 498.44 Myristoleyl arachidonate 
4 5.41 521.33 C26H50O10 522.34 Polysorbate 20 
5 5.8 187.14 C9H20N2O2 188.15 7,8-Diaminononanoate 
6 6.39 329.23 C14H18O9 330.23 Vanilloyl glucose 
7 6.53 329.22 C14H18O9 330.23 Vanilloyl glucose 
8 7.46 663.42 C35H60N4O6S 664.42 Prostaglandin F2α-biotin 
9 7.92 447.38 C21H22O11 448.38 
Kaempferol 7-O-β -D-
glucopyranoside 
10 8.58 1233.81 C63H114N2O21 1234.79 Ganglioside 
11 9.6 329.32 C14H18O9 330.23 Vanilloyl glucose 
12 10.01 375.28 Unknown      
13 11.03 463.37 C18H38N6O4 464.37 Quercetin 7-O-β-D-glucoside 
14 12.09 236.17 C13H19NO3 237.17 3-O-Methylrimiterol 
15 12.53 580.47 Unknown      
16 13.53 383.27 C17H32N6O4 384.24 Arg Pro Leu 
17 14.64 313.32 C19H38O3 314.28 2-hydroxy-nonadecanoic acid 
18 16.25 315.33 C18H36O4 316.26 9,12-dihydroxy stearic acid 
19 17.12 311.25 C13H12O9. 312.25 Caffeoyl tartrate 
20 17.49 295.3 C20H40O 296.30 Phytol 
21 18.14 293.29 C15H22N2O4 294.29 Sinapoyl putrescine 
22 18.68 297.32 C20H42O 298.3236 Phytanol 
23 19.04 566.48 C24H45N11O5 567.36 Lys His Lys Arg 
24 21.27 277.28 Unknown      
25 21.47 227.26 Unknown      
26 22.05 279.3 Unknown      
27 22.78 281.33 Unknown      
28 23.07 325.28 C15H18O8 326.29 Coumaric acid glucoside 
*A list of putative identifications was retrieved from HMDB, Metlin, MMCD, and LipidMaps databases. 
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Figure 1: Separation of different aminoacids from BMAE using HPLC-FLD at excitation wavelength- 
250 nm emission wavelength- 395 nm. (1: aspartic acid, 2: serine, 3: glutamic acid, 4: glycine, 5: histi-
dine, 6: arginine, 7: threonine, 8: alanine, 9: proline, 10: cystiene, 11: tyrosine, 1: valine, 13: methio-
nine, 14: lysine, 15: isoleucine, 16: leucine, 17: phenyl alanine) 
 
 
Table 2: Analysis of amino acids in BMAE using HPLC-FLD 
S. No. Amino acid Retention time Content (Mean ± SD) 
ng/g 
1 Aspartic acid 12.896 95.37±0.53 
2 Serine 13.648 99.54±0.68 
3 Glutamic acid 14.464 23.26±0.18 
4 Glycine 14.876 5.64±0.08 
5 Histidine 15.556 29.76±0.34 
6 Arginine 19.438 8.34±0.02 
7 Threonine 19.882 26.04±0.16 
8 Alanine 19.991 46.88±0.65 
9 Proline 21.376 131.5±1.91 
10 Cystiene 27.269 477.90±2.89 
11 Tyrosine 27.690 4.73±0.007 
12 Valine 28.636 9.97±0.069 
13 Methionine 29.213 243.08±1.29 
14 Ly sine 31.415 41.10±0.28 
15 Isoleucine 31.978 2.42±0.01 
16 Leucine 32.525 28.58±0.31 
17 Phenyl alanine 33.287 7.58±0.06 
 
 
The BMAE showed a concentration-
dependent antioxidant activity by inhibiting 
super oxide radical with an IC50 value of 
30.6 μg mL-1, whereas IC50 value of ascorbic 
acid was found to be 14.9 μg mL-1(Figure 
2B). Similarly, results of hydrogen peroxide 
scavenging activity for BMAE showed dose 
dependent activity between 5.0 - 35 μg mL1 
with IC50 value at 14.05 μg mL-1 and ascor-
bic acid at 6.77 μg mL-1(Figure 2A). 
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Figure 2: Dose response curve showing log 
concentration (µg/ml) vs % inhibition of H2O2 
scavenging assay (A) and superoxide scaveng-
ing assay (B) for Bombyx mori aqueous extract. 
 
 
Biochemical estimation  
There was marked elevation in the mean 
serum CK-MB level of DOX treated group 
as compared to control group (P<0.01 vs 
CNT). Treatment with BMAE and DFX 
showed significant reduction (P<0.01 vs 
DOX) in the CK-MB levels when compared 
to toxicant group (Table 3). Results of LDH 
estimation showed significant (P<0.01 vs 
CNT) elevation in the mean serum LDH lev-
el of DOX treated group in comparison to 
control group. Whereas, groups treated with 
BMAE and DFX showed significant reduc-
tion (P<0.01 vs DOX) in mean serum LDH 
level as compared to toxicant group (Table 
2). The mean tissue MDA and caspase-3 lev-
els (nmol mg-1 of protein) of DOX treated 
group were found significantly higher 
(P<0.01vs CNT), which were significantly 
reversed after treatment with BMAE and 
DFX (P<0.01 vs DOX) (Figure 3). DOX 
treated group also showed significant eleva-
tion (P<0.01 vs CNT) in serum TNF-alpha, 
IL-6 and tissue caspase-3 levels as compared 
to control group. Whereas, DFX and BMAE 
treated groups at 30 and 60 mg kg-1 showed 
significant reversal (P<0.01) to DOX toxicity 
of TNF-alpha, IL-6 as well as caspase-3 lev-
els (Table 4). 
 
 
Table 3: Effect of BMAE (30 mg/kg and 
60 mg/kg) on serum lactate dehydrogenase and 
creatine kinase-MB levels against doxorubicin-
induced cardiotoxicity in rats 
Group LDH 
(U/L) 
CK-MB 
(U/L) 
CONTROL 845.09±57 624.56±64 
DOX 1914.19±62# 2133.29±86#
DFX 964.69±27** 698.96±40**
DOX+BMAE30 1477±57** 1461.80±47**
DOX+BMAE60 1350.4±27** 1316.77±29** 
Each value is represented as mean ± SD. No. of 
animals (n) = 6. #P<0.01 when toxic control com-
pared with control, **P<0.01 vs toxic control. One 
way ANOVA followed by Dunnett’s t-test. CK-
MB: creatine kinase-MB; DOX: doxorubicin; 
LDH: lactate dehydrogenase; DFX: desferriox-
amine 
 
 
 
 
Figure 3: Effect of BMAE on cardiac caspase-
3(A) and cardiac malondialdehyde (B) on doxo-
rubicin (DOX)-induced cardiotoxicity in rats. Val-
ues are mean ± SD (n = 6). #P<0.01 when toxic 
control compared with control, ¥P<0.01 vs toxic 
control. One way ANOVA followed by Dunnett’s 
t-test. 
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Table 4: Effect of BMAE (30 mg/kg and 60 mg/ 
kg) on serum tumor necrosis factor-α, interleukin-
6 levels against doxorubicin-induced cardiotoxici-
ty in rats 
Group TNF-α 
(pg/mL) 
Interleukin-6 
(pg/mL) 
CONTROL 0.010±0.0003 82.25±0.95 
DOX 0.061±0.001# 429.25±8.26#
DFX 0.025±0.0007** 146.5±4.04**
DOX+BMAE30 0.041±0.001** 252.5±10.53**
DOX+BMAE60 0.040±0.0005** 227.25±11.67** 
Each value is represented as mean ± SD. No. of 
animals (n) = 6. #P<0.01 when toxic control com-
pared with control, **P<0.01 vs toxic control. One 
way ANOVA followed by Dunnett’s t-test. TNF-α: 
Tumor necrosis factor; IL-6: Interleukin-6; DOX: 
doxorubicin; DFX: desferrioxamine 
 
 
Histopathology 
The cardiac tissue samples belonging to 
CNT, DOX, BMAE and DFX treated groups 
were examined with special reference to my-
ocardial fiber integrity and histological evi-
dence of DOX induced cardiac damage. 
CNT group showed normal myocardial 
structure, whereas DOX treated group 
showed disarray of myocardial cells with 
small and large vacuolar myopathy. Howev-
er, there was no evidence of necrosis of the 
myocardium. The heart samples from the 
BMAE treated group at 30 and 60 mg Kg-1 
day-1 as well as STD group showed a normal 
myocardium with no evidence of vacuolar 
myopathy (Figure 4). 
 
DISCUSSION 
Doxorubicin (DOX) is an excellent 
antineoplastic agent for treating several types 
of hematological and solid malignancies 
(Shah et al., 2012; Pathan et al., 2012). Pre-
viously, DOX related cardiotoxicities are 
well documented; DOX is metabolically re-
duced to highly reactive free radicals, which 
generates superoxide and hydrogen peroxide. 
These highly toxic free radicals cause lipid 
peroxidation, inhibition of long chain fatty 
acids (Khan et al., 2014; Nohl et al., 1998) 
and cause damage to cellular components.  
The aqueous extract/decoction of 
Bombyx mori has been used since long in the 
Unani System of Medicine as a part of many 
of such formulations for the treatment of 
heart diseases. Some of the studies have al-
ready been reported earlier on alcoholic ex-
tract and on cocoon as such (crude) for its 
hypolipidemic potential (Mahmood et al., 
2013), cardioprotective activity against DOX 
induced cardiotoxicity and isoprenaline in-
duced myocardial necrosis (Kumar et al., 
2013; Nazmi et al., 2013). However, effect 
of B. mori aqueous extract in prevention of 
cardiac toxicity is yet to be established. 
Hence, we envisaged to evaluate the cardio-
protective potential of the standardized 
aqueous extract (freeze dried and powdered) 
for scientific validation of its use in tradi-
tional formulations as a major cardioprotec-
tive agent. 
In the present investigation DOX pro-
duced a significant cardiotoxicity at the acute 
dose of (20 mg/Kg/i.p./single dose) in male 
Wistar rats as evident by increased levels of 
serum LDH and CK-MB whereas reduced 
MDA and caspase-3 levels in cardiac tissue. 
The results were further supported by histo-
pathological studies of cardiac tissue, which 
is consistent with previous work (Ayla et al., 
2011; Mokni et al., 2012) in which signifi-
cant acute cardiotoxicity was reported in rats 
24 h after DOX treatment i.e. 20 mg/Kg/ 
i.p./single dose. In the present study, pre-
treatment with B. mori aqueous extract 
(BMAE) at a dose of 30 and 60 mg/Kg sig-
nificantly suppressed cardiac toxicity in-
duced by DOX. The protective effect of 
BMAE against DOX-induced cardiovascular 
damage is due to its prominent anti-oxidant 
activity. 
Increased level of different enzymes is 
possibly a reflection that the DOX treatment 
induces cardiac tissue damage, whereas LDH 
and CK-MB are relatively specific for myo-
cardial damage (Yagmurca et al., 2003). In 
the present study, marked elevation in the 
activities of LDH and CK-MB in the serum
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Figure 4: Effect of BMAE on cardiac tissue against doxorubicin (DOX)-induced cardiotoxicity in rats. 
Representative photographs of cardiac tissues are stained with hematoxylin and eosin, ×100. (CON): 
A representative section from control group showing unremarkable changes. (DOX): Sections from 
DOX-treated group showing myocardial degeneration (arrow in DOX) and perinuclear vacuolization. 
Histological improvement of lesions is seen in both BMAE 30 group (3) and BMAE 60 group (4) as 
well as in DFX group (5). 
 
of doxorubicin intoxicated rats were ob-
served (P<0.01), which are in agreement 
with Abdel-Sattar and colleagues (2012). 
Shah and colleagues (2012) who reported 
significant increase in serum LDH and CK-
MB level after a single dose of doxorubicin 
20 mg/Kg. The rise in serum LDH and CK-
MB level suggests an increased leakage of 
this enzyme from cardiac tissues into the 
systemic circulation after DOX treatment. 
However, treatment of rats with BMAE (30 
and 60 mg/Kg), LDH and CK-MB level was 
decreased to a level near to that of the con-
trol group. This protective effect could be 
attributed due to the antioxidant property and 
presence of various amino acids and flavo-
noids in B. mori. Significant increase in 
MDA content (an index of lipid peroxida-
tion) in cardiac tissues, of DOX induced rats 
has been observed, which correlates with the 
previous studies (Fard et al., 2010; Hadi et 
al., 2012; Abdel-Wahab et al., 2003). The 
pretreatment with BMAE decrease the oxida-
tive stress and lowers the level of MDA in 
cardiac tissues indicating decrease in oxida-
tive stress and lipid peroxidation. 
Free radicals may directly disrupt lipid 
membranes and they may also mediate the 
activation of genes for some pro-inflamma-
tory cytokines (TNF-α, IL-1, IL-6) (Schreck 
and Baeuerle, 1991). In our study, rise in the 
levels of inflammatory cytokine (TNF-α, IL-
6) (P<0.01) was found in DOX treated group 
as compared to control group which are in 
agreement with that of previously reported 
work (Elbaky et al., 2010; Bien et al., 2007; 
Moore et al., 2001). Pretreatment with 
BMAE, significantly lowered (P<0.01) the 
levels of TNF-α and IL-6, which may be due 
to its antioxidant property.  
DOX treatment increased the production 
of free radicals and activates the caspase-3, a 
major effector caspase that plays a critical 
role in the apoptotic cascade. In the present 
investigation increase in the caspase activity 
in cardiac tissue of DOX treated rats was ob-
served which supports the results of Yang 
and colleagues (2006), Ueno and colleagues 
(2006), who reported increase in caspase-3 
activity in DOX induced cardio-toxicity. Pre-
treatment with BMAE before DOX admin-
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istration lowers the cardiac caspase-3 levels 
by inhibiting apoptosis. 
The results of present investigations vali-
dated scientifically its use in various Unani 
formulations such as Khamira Abresham 
Hakim Arshadwala, Khamira Abresham Sa-
da etc. which is in agreement with earlier 
reports on Khamira’s for cardioprotection 
(Goyal et al., 2010). 
Histological observations further confirm 
the DOX induced disarray of myocardial fi-
bers and vacuolization. These deleterious 
changes seem resistent on pretreatment with 
BMAE. These observations provide convinc-
ing microscopic evidences regarding the car-
dioprotective potential of BMAE. Parame-
ters investigated here indicated that aqueous 
extract of BM is potent in alleviating DOX 
induced myocardial damage and ameliora-
tion of heart vacuolation. The observed re-
sults have been attributed to its free radicals 
scavenging capability, and to regulate the 
generation of inflammatory mediators. 
 
CONCLUSION 
On the basis of these findings it can be 
concluded that aqueous extract of BM has 
cardioprotective potential. This may be due 
to high content of amino acid and flavonoid 
in BMAE. The mechanism of cardioprotec-
tion may involve reduction in apoptotic fac-
tor (caspase-3 and TNF-alpha), oxidative 
stress (MDA), cardiac enzyme activity (CK-
MB and LDH) as well as proinflammatory 
(interleukin-6) marker. 
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